Clinical Trial Update: Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 study comparing triple therapy (oral treprostinil, ambrisentan, and tadalafil) with dual therapy (ambrisentan, tadalafil, and placebo) for pulmonary a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Adcirca (tadalafil)
• LETAIRIS (ambrisentan)
• Orenitram (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: WITHDRAWN